Royce & Associates LP Cara Therapeutics, Inc. Transaction History

Royce & Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$8.88 - $12.77 $105,290 - $151,413	-11,857 Reduced 5.54%	202,300 $2.17 Million
Q3 2022 Nov 03, 2022	BUY	$8.24 - $12.56 $936,138 - $1.43 Million	113,609 Added 112.99%	214,157 $2.01 Million
Q2 2022 Aug 04, 2022	SELL	$7.45 - $13.84 $82,277 - $152,848	-11,044 Reduced 9.9%	100,548 $918,000
Q1 2022 May 05, 2022	BUY	$9.94 - $12.65 $977,797 - $1.24 Million	98,370 Added 743.99%	111,592 $1.36 Million
Q4 2021 Feb 07, 2022	SELL	$11.99 - $18.14 $23,044 - $34,865	-1,922 Reduced 12.69%	13,222 $161,000
Q3 2021 Nov 10, 2021	BUY	$11.55 - $16.06 $174,913 - $243,212	15,144 New	15,144 $234,000

16.5M

55K

500

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.1M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.